Cor­rect­ed: Zevra CEO hits the ex­it as mi­nor­i­ty share­hold­er's nom­i­nees take board seats

Drug de­vel­op­er Zevra Ther­a­peu­tics, for­mer­ly known as Kem­Pharm, is con­tin­u­ing to make some changes to its lead­er­ship struc­ture.

On Mon­day, the Flori­da-based com­pa­ny an­nounced that CEO Richard Pas­coe has re­signed, ef­fec­tive on June 1. The board will ap­point an in­ter­im CEO as soon as pos­si­ble, per a press re­lease, with that process start­ing im­me­di­ate­ly. Pas­coe was al­so not re­elect­ed to the board last month as well.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER